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Summary
Bisphosphonates (BPs) are anticatabolic drugs of choice for treating bone diseases, including 
bone metastases. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is one of the possible 
complications. Crosslaps (CTX) could be used as biochemical marker for risk of developing ONJ. Vitamin 
D (VD) may be involved in this condition. VD status and CTX levels were evaluated and compared in BP-
treated women without BRONJ (Group I; n=28) and with BRONJ (Group II; n=58). Women were older and 
duration of BP use was longer in Group II (p=0.0000036). No differences in calcemia, phosphatemia, or 
CTX levels were observed; BAP levels were significantly higher and 25OHD were significantly lower in 
Group II (p=0.040 and p=0.035, respectively). The percentage of subjects with CTX levels between 100 
and 149mg/mL was similar in both groups. VD deficiency was observed in 18% of subjects in Group II 
but in none of the subjects in Group I. No significant differences in the percentage of subjects with VD 
insufficiency and sufficiency were observed between groups (Group I: 50%; Group II: 40%). Conclusion: 
CTX levels did not prove useful as predictors of risk for developing BRONJ. The high percentage of women 
with VD deficiency who developed BRONJ suggests a possible relationship between both conditions and 
highlights the importance of assessing Vitamin D status. 
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What are Glucocorticoids?
Bisphosphonates (BPs) are the anti-catabolic treatment of choice for osteoporosis and 
other bone diseases [1]. Therapeutic response to BPs is affected by Vitamin D (VD) status, 
which is determined by 25hydroxyvitamin D (25OHD) levels [2].
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is one of the possible 
complications of chronic oral or intravenous treatment with aminoBPs [3]. In 2007, the 
American Association of Oral and Maxillofacial Surgeons (AAOMS) defined this side effect of 
BP treatment as an area of exposed bone in the maxillofacial region in a patient on BP therapy 
for more than eight weeks and who has not had radiation therapy to the head and neck region 
[4]. Although the etiology of BRONJ is multifactorial, the marked decrease in bone remodeling 
would be one of the main risk factors for its development [5].
Bone remodeling involves two highly coordinated events, namely bone formation due to 
osteoblastic activity and bone resorption caused by osteoclastic activity. Bone cell activity 
can be assessed using biochemical markers of bone formation and resorption. These markers 
are used routinely to evaluate response to antiresorptive treatment. Through their action 
on the mevalonate pathway, BPs block osteoclast activity and favor cell apoptosis inhibiting 
bone resorption. Bone remodeling starts with a resorption event, so that inhibition of bone 
resorption dramatically decreases bone tissue remodeling [6].
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C-terminal telopeptide of collagen type I (CTX or Crosslaps) 
is currently considered the most sensitive and specific marker of 
bone resorption to assess changes in bone remodeling. Serum CTX 
levels decrease markedly within the first weeks or month after 
initiating anti catabolic treatment [7]. A new role for CTX has been 
suggested over the last years. According to Marx RE et al., very low 
serum CTX levels in patients on chronic BP therapy would indicate 
potential risk for developing BRONJ [8]. Other authors, however, 
found no relation between CTX levels and development of BRONJ 
[9,10] and the clinical utility of CTX as a predictor of BRONJ remains 
controversial to date [11-14].
Bedogni A et al. [15] found that 77% of patients with BRONJ 
but only 5% of BP-treated patients who did not develop BRONJ had 
osteomalacia [15]. Inadequate Vitamin D status has therefore been 
proposed as an additional risk factor for ONJ in patients on long-
term treatment with bisphosphonates.
Based on the above, the present study sought to evaluate and 
compare the VD status and CTX levels of women on chronic BP 
therapy with and without BRONJ.
Materials and Methods
Subjects
The subjects were recruited from a population of 25.538 
male and female patients, mean age 55±12 treated at the Oral 
and Maxillofacial Traumatology and Surgery Department II of the 
School of Dentistry, University of Buenos Aires (FOUBA), between 
2007 and 2013. The present study included all the female patients 
aged more than 20 years referred for oral surgery by their attending 
dentist or physician during the study period. All subjects signed a 
written informed consent form prior to enrollment.
The present study was conducted in keeping with ANMAT 
5330/97 guidelines and regulations, and in compliance with 
the Helsinki declaration and UNESCO bioethics principles. The 
study was approved by the Ethics Committee of the institution 
(Resolution (CD) 399).
Methods
From a total 253 women on long-term treatment with BPs 
(mean age: 62.4±6.7 years) referred for oral surgery to the 
department within the study period, 86 complied with the study 
inclusion criteria and were assigned to one of two groups according 
to the presence of BRONJ.
Group I (n=28): women receiving BPs who did not develop 
BRONJ.
Group II (n=58): women receiving BPs who developed BRONJ.
Clinical diagnosis of BRONJ was made according to the 2014 
update of the American Association of Oral and Maxillofacial 
Surgery position papers on medication-related osteonecrosis 
of the jaw [3]. Based on these guidelines, patients with a history 
of radiation therapy to the head and neck, presenting a systemic 
disease that alters normal physiology of bone tissue, and/or 
who did not consent to participate in the study or to undergo the 
biochemical assessments of bone and phospho-calcium metabolism 
were excluded from the study. BRONJ diagnosis was confirmed by 
clinical assessment.
At the first consultation of each participant, a patient interview 
was conducted and oral examination was performed to assess 
clinical signs and symptoms, neural signs and symptoms, and 
presence of oral lesions. The patient’s medication, underlying 
disease (osteoporosis, Paget’s disease, cancer) prompting BP 
therapy, and type of BP and duration of use regardless of dose were 
recorded. In the case of referred patients, their referring physician 
was reached to inquire about BP therapy. Post-operative follow 
up was performed at 1, 2, 4, 8, and 10 weeks post-surgery, and 
additional follow up visits were scheduled when necessary.
Phosphatemia (sPi) (mg/dL) was determined by colorimetry at 
340nm using an autoanalyzer (Abbott Laboratories, Abbott Park, 
IL, USA). Intra- and interassay coefficients of variation (CVs) were 
0.5-5% and 0.3-0.6%, respectively. Bone alkaline phosphatase 
(BAP) (IU/L) was determined by colorimetry at 520nm (optimized 
Alkaline Phosphatase, Wiener SA) after precipitation of the bone 
isoform with wheat germ lectin. Intra- and interassay CVs were 
between 4-8% and 6-8%, respectively.
Levels of 25 hydroxyvitamin D (25OHD) (ng/mL) were 
determined by competitive protein binding radioimmunoassay 
(DiaSorin, Stillwater, MN, USA). Intra- and interassay CVs were 
10% and 15%, respectively. C-terminal telopeptide of Collagen type 
I (CTX) (ng/mL) was determined by enzyme immunoassay using 
monoclonal antibodies (Osteometer BioTech, Herlev, Denmark). 
Intra-assay CV was 6%.
Statistical analysis
Normality of the studied variables was tested using Shapiro-
Wilk test. Homogeneity of variances was determined using 
Levene’s test. Student’s t test was used to compare the differences 
between the studied groups. All statistical analyses were performed 
using SPSS 19.0 for Windows (SPSS, Inc. Chicago, IL). Statistical 
significance was set at a value of p below 0.05 (p<0.05).
Result
Data corresponding to the 86 women included in the study 
are shown in Figure 1. Twenty-seven of the 28 women in Group I 
were prescribed BPs for osteoporosis and one for Paget’s disease, 
whereas 40 of the 58 women in Group II were prescribed BPs for 
osteopenia/osteoporosis and 18 for cancer treatment. Twenty-four 
women in Group I had undergone tooth extraction and one had 
had dental implant surgery. Eighty-six percent of patients (n=50) 
in Group II, 34 of whom had osteoporosis and 16 had a neoplasm, 
developed BRONJ after tooth extraction or dental implant therapy; 
the remaining 8 patients in this group, six of whom had osteoporosis 
and 2 had a neoplasm, developed ONJ spontaneously. 
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Figure 1: Distribution of women in Groups I and II according to underlying disease, type of oral treatment, and 
occurrence of bisphosphonate related osteonecrosis of the jaw.
Comparison between women with and without BRONJ
Comparison between groups showed women with BRONJ were 
older and duration of BP use was significantly longer (p=0.00001) 
in the group of women with BRONJ. No significant differences in 
serum calcium, phosphate, or CTX levels were observed between 
groups, whereas BAP levels were significantly higher and 25OHD 
levels were significantly lower in the group of women who 
developed BRONJ (p=0.040 and p=0.035, respectively) Table 1. In 
view of the highly significant differences in duration of use between 
groups I and II, all the above parameters were analyzed in a subset 
of patients with BRONJ whose duration of BP use was similar to that 
of Group I, i.e., women who did not develop BRONJ. As observed 
when comparing the entire Group I with Group II, mean age of 
the Group II subset was higher than mean age of Group I, but no 
significant differences in serum calcium, phosphate, or CTX levels 
were observed between the Group II subset and Group I (data not 
shown).
Table 1: Data of the women included in the study.
Group I (n=28) Group II (n=58)
Age 61.0±8.2 66.2±9.8
Duration of BP use 36.8±23.3 63.9±41.7**
Calcemia (mg/dL) 9.4±0.4 9.4±0.6
Phosphatemia (mg/dL) 3.4±0.7 3.4±0.5
BAP (IU/L) 60.2±24.4 73.7±34.3*
CTX (ng/mL) 226±171 224±151
25OHD (ng/mL) 32.5±9.7 28.4±9.4*
*P <0.05; **p<0.00001  : Group I vs. Group II
Figure 2: Percentage of women in Groups I and II 
according to CTX (A) and according to 25OHD levels (B).
Distribution of patients in Groups I and II according to serum 
CTX levels stratified as high, low, or minimal risk for BRONJ (8) 
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is shown in Figure 2. No statistically significant differences in the 
percentage of women with CTX levels between 100 and 149mg/
mL (14.3% and 19.0%) or between women with CTX >301 mg/
mL (28.5% vs. 33.4%) were observed between groups. However, 
50% of women in Group II had CTX levels <100mg/mL (14.3% 
vs. 23.8%), and the number of women with CTX levels in the 150-
300mg/mL range (42.9% vs. 23.8%) was twofold higher in Group II 
as compared to Group I.
Comparison of duration of use and 25OHD levels between 
groups according to range of CTX showed significantly lower 
duration of use (p<0.0001) in each of the CTX ranges, and 
significantly higher 25OHD levels (p<0.05) in the <100 and 150-
300 mg/mL CTX ranges in Group I Table 2.
Table 2: Data of women with and without BRONJ according to CTX levels.
CTX levels <100  100-149  150-300  
 Group I Group II Group I Group II Group I Group II
CTX (mg/mL) 57±23 49±26 115±18 127±18 222±49 214±36
Age (years) 64.8±12.2 61.4±9.4 55.8±4.6* 69.6±11.2 60.4±9.3 68.0±10.6
Type of Oral tr. 32.6±23.6* 59.4±66.4 27.0±11.5* 65.8±26.6 42.8±27.1* 64.9±38.2
BAP (IU/L) 56.0±13.8* 83.0±38.8 59.0±10.5 61.0±15.8 60.8±4.3* 80.8±43.7
25OHD (ng/mL) 31.4±5.0 31±8.2 30.1±4.6 33.8±4.9 37.7±12.7* 27.5±10.0
Vitamin D status (sufficiency, insufficiency, deficiency) in each 
group is shown in Figure 1. Whereas none of the subjects in Group I 
had deficient VD levels, 18% of those in group II had 25OHD levels 
below 20 ng/ml. The percentage of women with VD sufficiency/ 
insufficiency did not differ significantly between groups, and 
accounted for 50% of women in Group I and 40% of those in Group 
II.
Comparison of duration of use in patients with VD sufficiency 
and insufficiency between groups, showed that duration of use was 
significantly lower (p<0.001) in patients with VD sufficiency and 
insufficiency in Group I. It was not possible to compare duration of 
use in patients with Vitamin D deficiency since there were no cases 
of Vitamin D deficiency in Group I Table 3.
Table 3: Data of women with and without BRONJ according to 25OHD levels.
25OHD levels <20 20-30 >30
 Group I Group II Group I Group II Group I Group II
25OHD (ng/mL) - 15.6±3.0 23.2±1.9 26.6±2.9 39.3±8.9 37.4±3.4
Age (years) - 63.5±10.6 60.0±3.0 68.6±8.7 60.7±8.9 65.9±10.4
Type of Tr. - 46.0±24.1 46.0±27.8 74.2±45.1 34.8±24.6 58.9±43.9
BAP (IU/L) - 88.3±29.9 72.5±42.0 77.2±41.5 55.9±10.0 68.6±27.9
CTX (mg/mL) - 212±90 317±239 292±192 208±138 206±149
Comparison of parameters according to onset of BRONJ showed 
that CTX levels were significantly higher (264±169 vs. 189±87mg/
mL; p<0.05) in women who developed BRONJ after invasive 
dental treatment as compared to those who developed BRONJ 
spontaneously, and though the difference did not reach statistical 
significance, duration of use (71.8±19.7 vs. 62.2±45.0 months) was 
also longer (71.8±19.7 vs. 62.2±45.0 months) in the former sub-set 
of women with BRONJ. No differences in age or in the remaining 
biochemical parameters were observed between these two sub-
sets.
As regards underlying disease prompting BP therapy, no 
significant differences in serum calcium (9.3±0.4 vs. 9.7±0.8mg/
dL), phosphate (3.4±0.6 vs. 3.4±0.9mg/dL), BAP (73.1±31.2 
vs. 79.3±38.5), or 25HOD (29.5±8.5 vs. 28.4±9.3mg/dL) levels 
were observed between women with BRONJ receiving BPs for 
osteoporosis and those receiving BPs for cancer treatment. Mean 
CTX levels were higher in women with BRONJ receiving BPs for 
cancer treatment than in those receiving BPs for osteoporosis 
(225±121 vs. 291±222mg/mL, respectively), though the 
difference did not reach statistical significance. Duration of use 
was significantly higher in BRONJ patients with osteoporosis 
than in those with a neoplasm (74.4±42.6 vs. 44.6±31.9 months, 
respectively: p<0.01).
The percentage of patients with BRONJ receiving BPs for 
osteoporosis and for cancer treatment according to serum CTX 
and 25OHD values is shown in Figure 3. The percentage of 
osteoporosis and cancer patients with CTX levels indicating high or 
moderate risk for BRONJ was similar (33.3% vs. 33.4%), whereas 
the percentage of cancer patients with CTX levels below 100mg/
mL was higher than that of women with osteoporosis (16.7% vs. 
9.6%). The percentage of subjects with deficient/inadequate VD 
levels was higher in the group of cancer patients (58.8% vs. 67.7%). 
Comparison of parameters according to mode of delivery (oral 
vs. intravenous administration) showed that serum Ca, BAP, CTX, 
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and 25OHD levels were higher and serum phosphate levels were 
lower in women receiving intravenous BPs, though only BAP levels 
differed significantly (70±5 vs. 97±10 IU/L; p<0.05).
Figure 3: Percentage distribution of women with osteoporosis and cancer according to CTX and 25OHD levels (A and 
B, respectively).
Discussion
Serum CTX levels were not found to predict risk for ONJ. Of 
note, a high percentage of patients on long-term BP treatment, 
including those who developed BRONJ and those who did not, had 
inadequate VD status.
The degree of bone turnover can be assessed using biochemical 
markers of bone remodeling, which include osteoblastic bone 
formation and osteoclastic bone resorption markers. When bone 
formation and resorption are coupled and coordinated, it is sufficient 
to determine one in order to assess total bone remodeling. CTX is 
currently considered one of the most specific and sensitive markers 
of bone resorption [16,17]. CTX levels decrease dramatically one 
or two months after initiation of oral or intravenous antiresorptive 
BP treatment. This decrease prevents bone mass loss, and the risk 
of fracture therefore decreases. However, suppression of bone 
remodeling for a prolonged period of time can cause adverse 
secondary effects such as atypical fractures and BRONJ [3].
Bisphosphonate-related osteonecrosis of the jaw is a 
complex condition of multifactorial origin, involving a number of 
mediators. The marked decrease in bone remodeling resulting 
from BP treatment is considered one of the key risk factors for the 
development of this disease [18]. However, there is a wide range of 
individual variability among patients receiving the same dose and 
even the same BP [14], likely due to genetic susceptibilities [19].
Biochemical determination of CTX levels reflects total bone 
resorption activity, rather than resorption at a specific skeletal site. 
In this regard, it must be kept in mind that the bone remodeling 
process in the jaws differs from that of the axial skeleton, and the 
jaws also differ in their response to aminobisphosphonate therapy. 
It has therefore been posited that BRONJ cannot develop without 
significant suppression of bone remodeling. Should the latter occur, 
minor trauma as is tooth extraction could trigger the disease. In this 
regard, Mark RE et al. concluded that the risk of BRONJ in patients 
on BP therapy for more than three years was high when their CTX 
levels were <100pg/mL, moderate with CTX levels 100 to 150pg/
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mL, and minimal with CTX values 150 a 299pg/mL. Based on the 
above, the 2009 update of the AAOMS guidelines recommended 
discontinuing BP therapy for three months prior to dental surgery 
(bisphosphonate holiday) in order to minimize risk of developing 
BRONJ [20]. However, due to their high affinity for hydroxyapatite, 
aminobisphosphonates remain in the bone microenvironment 
over long periods of time, with the more potent BPs remaining 
in the body up to10 years. It would therefore be unlikely for the 
concentration of BP in the bone to change at such short times. A 
number of researchers [21-23] have also lent support to the utility 
of CTX levels as a potential risk predictor of BRONJ, though more 
recent studies seem to challenge this conclusion [22,24]. In their 
2011 report, the American Dental Association Council on Scientific 
Affairs (ADAC) concluded that there was not sufficient evidence 
to consider the different levels of biochemical markers of bone 
remodeling as risk predictors for developing BRONJ [25]. The 2014 
update of the AAOMS further supported the lack of validation of a 
systemic marker of bone remodeling to assess the risk for BRONJ 
[3].
In agreement with the above reports, we found no difference 
in average CTX levels or in the percentage of women with CTX 
levels in the low, moderate, and high risk ranges between patients 
with and without BRONJ. CTX levels were only found to differ 
within the group of BRONJ patients, and were lower in those who 
developed BRONJ spontaneously than in those who developed 
BRONJ after invasive dental treatment. Fifty percent of women with 
spontaneous BRONJ but only 25% of those with dental treatment-
induced BRONJ had CTX levels below 150mg/mL. According to 
the classification proposed by Mark RE et al., therefore, 50% and 
75% of patients with spontaneous and trauma-induced BRONJ 
respectively were at minimal risk of developing the disease, though 
100% of these patients in fact developed BRONJ [8].
Other additional risk factors for BRONJ that would affect 
CTX levels include age, invasive oral treatment, type of BP, dose, 
and duration of use [26]. Both groups of women treated with 
BPs were similar in age, and all underwent oral treatment (tooth 
extraction or implant surgery), but differed in duration of use and 
type of BP. Although there were no available data on the dose, it is 
well documented that the dose used to treat neoplasms or active 
Paget’s disease is markedly higher than the dose used to treat 
osteopenia/osteoporosis. The mode of delivery also differs with 
regard to the aforementioned conditions: neoplasms and Paget’s 
disease are usually treated with intravenously administered 
BPs, whereas osteoporosis/osteopenia are treated with oral BPs. 
Intravenous administration of BPs has been associated with high 
risk of developing BRONJ [27]. Nevertheless, our results showed 
no difference in mean CTX levels or in the percentage of women 
with CTX levels <150mg/mL when comparing women receiving 
intravenous and oral BPs (data not shown).
Because BPs deposit in the bone, the quantity of the drug 
that remains in the bone microenvironment will depend on 
duration of treatment. In the present study, duration of treatment 
with aminoBPs was two-fold higher in the group of women who 
developed BRONJ than in the group who did not. In addition, our 
results showed that duration of use was shorter among the cancer 
patients than the osteoporosis patients who developed BRONJ. 
Despite these differences, according to reports in the literature, CTX 
levels stabilize after six weeks of treatment and are independent 
of treatment duration [23]. In line with these findings, our results 
showed that duration of treatment did not affect mean CTX levels 
or the percentage of women with CTX levels below 150mg/mL. 
The type of BP also differed. Intravenous zoledronate was the 
treatment of choice for neoplasms but zoledronate was not used 
for osteoporosis treatment (50% vs. 0%, respectively). Conversely, 
oral alendronate was not used to treat neoplasms but was the 
choice treatment for osteoporosis (0% vs. 38%, respectively). The 
observed difference in the type of aminoBP and mode of delivery 
did not affect mean CTX levels or the percentage of women with 
CTX levels below 150mg/mL (data not shown).
It must be pointed out that although the present results do not 
lend support to the utility of serum CTX levels as predictor of risk 
for developing BRONJ, it is important to maintain the levels of this 
bone marker within reference range in order to prevent potential 
adverse effects of BP therapy.
Treatment with BPs can induce hypocalcemia and subsequently 
hyperparathyroidism [28]. According to reports in the literature, 
hyperparathyroidism may be involved in the complex etiology 
of BRONJ, since patients who develop BRONJ have persistent 
hypocalcemia and secondary hyperparathyroidism during the 
period before the onset of BRONJ [29]. Hellstein JW et al. [25] found 
that patients with higher immunoreactive PTH levels prior to or 
during BP treatment were more likely to develop BRONJ than those 
showing normal iPTH before PB treatment. Because PTH levels 
were not determined in all the women included in the present study, 
we were not able to evaluate the relation between PTH levels prior 
to BP treatment and development of BRONJ. Nevertheless, none of 
the women studied here had hypocalcemia, a specific marker of an 
increase in the parathyroid secretion.
Vitamin D deficiency has been considered a possible risk factor 
for BRONJ. In this regard, Hokugo A et al. [27] found VD deficient-
rats treated with zoledronate to be at higher risk for BRONJ [27]. 
Clinical studies conducted by Beddoni A et al. showed a strong 
association between VD deficiency and risk for developing BRONJ 
[15]. Vitamin D deficiency and hyperparathyroidism are associated 
since insufficient 25OHD levels increase PTH levels through loss 
of negative feedback of VD on parathyroid hormone synthesis 
and secretion [27,30]. It is therefore relevant to consider whether 
increased iPTH levels, VD insufficiency, or both combined may 
play a role in the onset of BRONJ. As mentioned above, iPTH levels 
were not assessed in the present study. Nevertheless, given that the 
mean 25OHD levels of women with BRONJ were lower than those 
of women without BRONJ, it could be hypothesized that PTH levels 
might have been higher, though still within the reference range, at 
least in women with 25OHD levels in the insufficiency range. The 
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lower mean 25OHD levels observed in the group of women with 
BRONJ are accounted for not only by the higher percentage of 
women with inadequate VD status in this group but also by the fact 
that approximately 20% of women in this group had VD deficiency.
Badros A et al. [31] found that 40% of patients with multiple 
myeloma had VD deficiency (<14.4ng/mL) and 35% had VD 
insufficiency (14.4 a 30ng/mL) [31]. Lowe LC et al. [32] reported 
that 30.2% patients with breast cancer had VD insufficiency [32]. 
Multiple myeloma and cancer patients are usually treated with high 
doses of BPs, so that these patients on long term treatment with 
BPs could develop BRONJ. Although each of the aforementioned 
authors reported the percentage of multiple myeloma and cancer 
patients with vitamin D insufficiency/deficiency, respectively, 
they did not provide information regarding the presence of BRONJ 
among the patients they included in their study. It could be thought 
that their study population may have included subjects receiving 
high doses of BPs and who also had VD insufficiency/deficiency, 
and were therefore at risk for developing BRONJ. We found 45% of 
cancer patients who developed BRONJ in the insufficiency range. 
However, because 100% percent of the BP-treated cancer patients 
in our study developed BRONJ, we could not establish comparisons 
with BP-treated patients without BRONJ [33].
It is well documented that bone metabolism is directly affected 
by BP therapy, though in a complex manner on account of the 
number of mediators involved. It is therefore important to maintain 
the different mediators within reference ranges for the proper 
pharmacological action of BPs. In this regard, there is consensus 
that the therapeutic efficacy of BPs in decreasing fracture risk is 
suboptimal under conditions of VD deficiency [2]. In the present 
study, however, 60% of BP-treated women who developed BRONJ 
and 50% of those who did not were in the VD insufficiency range.
To conclude, the present results do not allow confirming the 
utility of serum CTX levels as predictor of risk for developing BRONJ. 
In addition, the high percentage of women with VD deficiency who 
developed BRONJ suggests the importance of determining the 
physiological status of bone metabolism in order to adjust calcium, 
VD, and PTH levels on account of the potential relation between 
these parameters and the development of BRONJ.
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